Oxaprozin adverse effects

Oxaprozin (Daypro) is approved for the treatment of osteoarthritis and rheumatoid arthritis. Its long half-life allows for once daily dosing. The most frequently reported adverse effects of this drug are nausea, vomiting, and dyspepsia. 

Pseudoporphyria is an infrequent adverse effect of some NSAIDs, including naproxen (SEDA-12, 87), nabu-metone (SEDA-16, 111), and oxaprozin (SEDA-21,106). 

In controlled studies, oxaprozin caused adverse effects in 23-58% of patients (1). It was considered better than aspirin and similar to other NSAIDs in long-term studies (2). However, treatment had to be interrupted owing to adverse effects in 8-31% of patients. 

Oxaprozin (Daypro) has similar pharmacological properties, adverse effects, and therapeutic uses to those of other propionic acid derivatives. However, its pharmacokinetic properties differ considerably. Peak plasma levels are not achieved until 3 to 6 hours after an oral dose, whereas its half-life of 40 to 60 hours allows for once-daily adminisffation. 

---